Article

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

2021-09-12

Abstract excerpt

<h4>Background</h4> Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate the safety and efficacy after two doses of BNT162b2 mRNA vaccination in five selected groups of immunocompromised patients and healthy controls. <h4>Methods</h4> 539 study subjects (449 patients and 90 contr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 402597ea-5f9e-5969-b886-6f0e903140e8
DOI: 10.1101/2021.09.07.21263206

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialDOI 10.1101/2021.09.07.21263206Read

HUMORAL AND CELLULAR IMMUNOGENICITY and SAFETY UP TO 4 MONTHS AFTER VACCINATION WITH BNT162B2 mRNA COVID-19 VACCINE IN HEART AND LUNG TRANSPLANTED YOUNG ADULTSSemantic proximity Read

Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipientsSemantic proximity Read

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines in Immunocompromised Individuals: A Systematic Review and Meta-Analysis Using the GRADE FrameworkSemantic proximity Read

Immunogenicity of COVID-19 mRNA Vaccines in Immunocompromised Patients: A Systematic Review and Meta-AnalysisSemantic proximity Read

Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patientsSemantic proximity Read

Immune Response and Reactogenicity After Immunization With a Suboptimal Two-Dose mRNA Vaccine Followed by a Full Vaccination With a Standard mRNA Vaccine Compared to a Prime-Boost Regimen of a Standard mRNA Vaccine: A Multicenter Cohort StudySemantic proximity Read

Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort StudySemantic proximity Read

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesSemantic proximity Read

Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population; A systematic review and meta-analysisSemantic proximity Read

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVacSemantic proximity Read

Cellular and Humoral Responses to SARS-CoV-2 Vaccination in Immunosuppressed PatientsSemantic proximity Read

The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responsesSemantic proximity Read